Jinju Kim

5PUBLICATIONS
10CO-AUTHORS
Medical infection agents (incl. prions)Environmental biogeochemistryHaematological tumoursMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Mar 27, 2025
Author Correction: Mutated IL-32θ (A94V) inhibits COX2, GM-CSF and CYP1A1 through AhR/ARNT and MAPKs/NF-κB/AP-1 in keratinocytes exposed to PM10.

Jinju Kim, Chae-Min Lim, Nahyun Kim

|Jan 15, 2025
Mutated IL-32θ (A94V) inhibits COX2, GM-CSF and CYP1A1 through AhR/ARNT and MAPKs/NF-κB/AP-1 in keratinocytes exposed to PM10.

Jinju Kim, Chae-Min Lim, Nahyun Kim

|Sep 02, 2023
Modulatory effects of point-mutated IL-32θ (A94V) on tumor progression in triple-negative breast cancer cells.

Hyo-Min Park, Jae-Young Park, Na-Yeon Kim

|Jun 02, 2021
Interleukin-32θ Triggers Cellular Senescence and Reduces Sensitivity to Doxorubicin-Mediated Cytotoxicity in MDA-MB-231 Cells.

Thu-Huyen Pham, Hyo-Min Park, Jinju Kim

|Dec 29, 2020
STAT3 and p53: Dual Target for Cancer Therapy.

Thu-Huyen Pham, Hyo-Min Park, Jinju Kim

Pageof 1

Frequent Collaborators

5 joint publications

Jin-Tae Hong

5 joint publications

Do-Young Yoon

3 joint publications

Thu-Huyen Pham

3 joint publications

Hyo-Min Park